Clinical Trial Update: Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear Palsy [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing continuous infusion of recombinant methionyl human GDNF for progressive supranuclear palsy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Supranuclear Palsy

Drugs mentioned

• Glial cell line-derived neurotrophic factor (GDNF) (glial cell line-derived neurotrophic factor)

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Progressive Supranuclear Palsy | Phase 2 | Status: COMPLETED